MedTrace Logo

A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer

NCT01656538 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2023-08-04

No results posted yet for this study

Summary

Researchers doing this study want to evaluate the side effects of Reolysin when given together with paclitaxel. As these drugs have not been given together before, 6-9 patients will be treated with paclitaxel plus reolysin to ensure that side effects are tolerable.

Conditions

Interventions

DRUG

Paclitaxel

DRUG

Reolysin

Sponsors & Collaborators

Principal Investigators

  • Vanessa Bernstein · BCCA - Vancouver Island Centre

  • Susan Ellard · BCCA-Cancer Ctr., Southern Interior

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-20
Primary Completion
2016-11-18
Completion
2018-02-14

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656538 on ClinicalTrials.gov